MANKINDMankind Pharma

₹2369.5-1.25%

Market Cap

₹98,333.52 Cr

Stock P/E

51.95

ROCE

18.32%

ROE

16.98%

Book Value

₹356.87

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Strong Q1 FY'26 start with 25% revenue growth and EBITDA margin at 23.8%
•
IPM-led momentum evidenced by 1.8x volume growth to IPM driven by anti-infectives and respiratory segments

NEGATIVES

•
Gross margins declined 130 bps YoY to 70.5% due to unfavorable mix and inventory-related accruals
•
PAT declined 17.4% YoY to Rs. 445 crores due to higher finance costs and depreciation from BSV consolidation

Peers Summary

Sector Leader

Mankind Pharma Ltd. showcases strong profitability and growth relative to its peers, while maintaining low debt levels, making it an attractive pick in the Pharmaceuticals & Drugs industry. However, it has a relatively high valuation compared to its growth prospects, suggesting a balanced outlook with potential caution for new investors.

Key Points

• Mankind Pharma has the highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).
• Dr. Reddy's Laboratories ranks highest in profitability metrics like ROE (21.76%) and EBITDA margin (27.09%).
• Mankind has a low debt-equity ratio (0.021), indicating strong financial stability.

Top Performers

Mankind Pharma Ltd.

Highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).

Dr. Reddy's Laboratories Ltd.

Highest ROE (21.76%) and significant profitability with low valuation metrics.

Cipla Ltd.

Best valuation attractiveness with a low PE (23.73) and high profitability.

Explore

Watchlists

Command Palette